Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis
Abstract Objective To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI). Methods A retrospective case series of 4 p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-05-01
|
| Series: | Journal of Ophthalmic Inflammation and Infection |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12348-025-00494-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729142560391168 |
|---|---|
| author | Battuya Ganbold Ba Trung Nguyen Jia-Horung Hung Azadeh Mobasserian Zheng Xian Thng Hashem Ghoraba Negin Yavari Dalia El Feky Cigdem Yasar Aim-On Saengsirinavin Xiaoyan Zhang Frances Andrea Anover S. Saeed Mohammadi Ngoc Tuong Trong Than Anadi Khatri Osama Elaraby Amir Akhavanrezayat Ankur Sudhir Gupta Woong Sun Yoo Quan Dong Nguyen Christopher Or |
| author_facet | Battuya Ganbold Ba Trung Nguyen Jia-Horung Hung Azadeh Mobasserian Zheng Xian Thng Hashem Ghoraba Negin Yavari Dalia El Feky Cigdem Yasar Aim-On Saengsirinavin Xiaoyan Zhang Frances Andrea Anover S. Saeed Mohammadi Ngoc Tuong Trong Than Anadi Khatri Osama Elaraby Amir Akhavanrezayat Ankur Sudhir Gupta Woong Sun Yoo Quan Dong Nguyen Christopher Or |
| author_sort | Battuya Ganbold |
| collection | DOAJ |
| description | Abstract Objective To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI). Methods A retrospective case series of 4 patients (6 eyes). Results In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI. Conclusion SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis. |
| format | Article |
| id | doaj-art-030fdecf7da4497c9f913314f7fef53a |
| institution | DOAJ |
| issn | 1869-5760 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Ophthalmic Inflammation and Infection |
| spelling | doaj-art-030fdecf7da4497c9f913314f7fef53a2025-08-20T03:09:19ZengSpringerOpenJournal of Ophthalmic Inflammation and Infection1869-57602025-05-011511810.1186/s12348-025-00494-6Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritisBattuya Ganbold0Ba Trung Nguyen1Jia-Horung Hung2Azadeh Mobasserian3Zheng Xian Thng4Hashem Ghoraba5Negin Yavari6Dalia El Feky7Cigdem Yasar8Aim-On Saengsirinavin9Xiaoyan Zhang10Frances Andrea Anover11S. Saeed Mohammadi12Ngoc Tuong13Trong Than14Anadi Khatri15Osama Elaraby16Amir Akhavanrezayat17Ankur Sudhir Gupta18Woong Sun Yoo19Quan Dong Nguyen20Christopher Or21Spencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversitySpencer Center for Vision Research, Byers Eye Institute at Stanford UniversityAbstract Objective To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI). Methods A retrospective case series of 4 patients (6 eyes). Results In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI. Conclusion SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.https://doi.org/10.1186/s12348-025-00494-6Non-infectious anterior scleritisSubconjunctival dexamethasone implantOzurdex® |
| spellingShingle | Battuya Ganbold Ba Trung Nguyen Jia-Horung Hung Azadeh Mobasserian Zheng Xian Thng Hashem Ghoraba Negin Yavari Dalia El Feky Cigdem Yasar Aim-On Saengsirinavin Xiaoyan Zhang Frances Andrea Anover S. Saeed Mohammadi Ngoc Tuong Trong Than Anadi Khatri Osama Elaraby Amir Akhavanrezayat Ankur Sudhir Gupta Woong Sun Yoo Quan Dong Nguyen Christopher Or Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis Journal of Ophthalmic Inflammation and Infection Non-infectious anterior scleritis Subconjunctival dexamethasone implant Ozurdex® |
| title | Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis |
| title_full | Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis |
| title_fullStr | Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis |
| title_full_unstemmed | Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis |
| title_short | Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis |
| title_sort | subconjunctival dexamethasone implant ozurdex r in the management of refractory non infectious anterior scleritis |
| topic | Non-infectious anterior scleritis Subconjunctival dexamethasone implant Ozurdex® |
| url | https://doi.org/10.1186/s12348-025-00494-6 |
| work_keys_str_mv | AT battuyaganbold subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT batrungnguyen subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT jiahorunghung subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT azadehmobasserian subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT zhengxianthng subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT hashemghoraba subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT neginyavari subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT daliaelfeky subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT cigdemyasar subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT aimonsaengsirinavin subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT xiaoyanzhang subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT francesandreaanover subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT ssaeedmohammadi subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT ngoctuong subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT trongthan subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT anadikhatri subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT osamaelaraby subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT amirakhavanrezayat subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT ankursudhirgupta subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT woongsunyoo subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT quandongnguyen subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis AT christopheror subconjunctivaldexamethasoneimplantozurdexinthemanagementofrefractorynoninfectiousanteriorscleritis |